Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 210,000 shares, a decline of 88.7% from the June 15th total of 1,854,604 shares. Based on an average trading volume of 22,065,408 shares, the short-interest ratio is presently 0.0 days.
Regen BioPharma Stock Performance
Shares of Regen BioPharma stock traded up $0.00 during trading hours on Friday, reaching $0.00. The stock had a trading volume of 109,012,373 shares, compared to its average volume of 15,064,843. Regen BioPharma has a 1 year low of $0.00 and a 1 year high of $0.12.
Regen BioPharma Company Profile
Regen BioPharma, Inc is a development?stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases.
Its primary activities include the discovery and preclinical validation of stem cell?derived receptors and peptides, the development of immuno?oncology assets, and the filing of investigational new drug (IND) applications to support first?in?human studies.
Read More
- Five stocks we like better than Regen BioPharma
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
